ERBB2 and non-small cell lung carcinoma: The ongoing phase III DESTINY-Lung04 trial (NCT05048797) will assess the efficacy and safety of T-DXd as single-agent therapy compared to chemotherapy plus pembrolizumab for first-line treatment in advanced NSCLC patients with HER2 exon 19 or 20 mutations.